PharmaSGP Holding SE
XETRA:PSG
PharmaSGP Holding SE
XETRA:PSG
Price:
24.6
EUR
-0.81%
Market Closed
Market Cap:
295.2m
EUR
Income Statement
Earnings Waterfall
PharmaSGP Holding SE
PharmaSGP Holding SE
|
Revenue
|
114m
EUR
|
|
Cost of Revenue
|
-10.3m
EUR
|
|
Gross Profit
|
103.7m
EUR
|
|
Operating Expenses
|
-76.9m
EUR
|
|
Operating Income
|
26.8m
EUR
|
|
Other Expenses
|
-8m
EUR
|
|
Net Income
|
18.8m
EUR
|
Income Statement
PharmaSGP Holding SE
PharmaSGP Holding SE
Currency: EUR
Millions
TTM
| Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Revenue |
63
N/A
|
64
+3%
|
65
+1%
|
65
+1%
|
63
-3%
|
59
-7%
|
56
-5%
|
61
+9%
|
65
+7%
|
74
+13%
|
81
+10%
|
83
+3%
|
86
+3%
|
89
+4%
|
94
+5%
|
98
+4%
|
101
+4%
|
107
+6%
|
110
+2%
|
114
+4%
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
(6)
|
(5)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(8)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
(10)
|
(10)
|
(10)
|
|
| Gross Profit |
57
N/A
|
59
+4%
|
59
+1%
|
60
+1%
|
57
-5%
|
53
-7%
|
50
-5%
|
55
+9%
|
59
+7%
|
66
+12%
|
72
+10%
|
74
+2%
|
77
+4%
|
80
+5%
|
85
+5%
|
88
+5%
|
92
+4%
|
98
+6%
|
100
+2%
|
104
+4%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(34)
|
(35)
|
(35)
|
(36)
|
(42)
|
(41)
|
(40)
|
(43)
|
(43)
|
(50)
|
(56)
|
(57)
|
(59)
|
(61)
|
(63)
|
(66)
|
(67)
|
(71)
|
(74)
|
(77)
|
|
| Selling, General & Administrative |
(30)
|
(11)
|
(18)
|
(19)
|
(35)
|
(11)
|
(5)
|
(5)
|
(36)
|
(5)
|
(5)
|
(5)
|
(44)
|
(56)
|
(68)
|
(79)
|
(51)
|
(54)
|
(56)
|
(58)
|
|
| Depreciation & Amortization |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(4)
|
(6)
|
(8)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
|
| Other Operating Expenses |
(4)
|
(24)
|
(16)
|
(16)
|
(7)
|
(28)
|
(35)
|
(37)
|
(4)
|
(39)
|
(43)
|
(43)
|
(6)
|
5
|
14
|
22
|
(7)
|
(8)
|
(9)
|
(9)
|
|
| Operating Income |
22
N/A
|
24
+5%
|
24
+4%
|
24
-2%
|
15
-39%
|
12
-21%
|
10
-10%
|
12
+12%
|
16
+37%
|
16
+1%
|
16
+2%
|
17
+1%
|
18
+7%
|
20
+11%
|
21
+9%
|
22
+5%
|
25
+10%
|
26
+7%
|
26
-1%
|
27
+3%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(2)
|
(2)
|
(2)
|
|
| Non-Reccuring Items |
0
|
(1)
|
(2)
|
(2)
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
22
N/A
|
23
+2%
|
23
-1%
|
22
-3%
|
14
-35%
|
11
-19%
|
10
-10%
|
11
+9%
|
14
+27%
|
15
+5%
|
15
0%
|
15
-1%
|
16
+8%
|
17
+10%
|
19
+8%
|
20
+6%
|
22
+10%
|
24
+10%
|
24
+1%
|
25
+3%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
(6)
|
(6)
|
(6)
|
(6)
|
(4)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(5)
|
(5)
|
(6)
|
(6)
|
(6)
|
|
| Income from Continuing Operations |
17
|
17
|
17
|
16
|
11
|
9
|
8
|
8
|
11
|
11
|
11
|
11
|
12
|
13
|
14
|
15
|
16
|
18
|
18
|
19
|
|
| Net Income (Common) |
17
N/A
|
17
+2%
|
17
-1%
|
16
-3%
|
11
-35%
|
9
-19%
|
8
-10%
|
8
+9%
|
11
+27%
|
11
+5%
|
11
0%
|
11
-1%
|
12
+9%
|
13
+10%
|
14
+8%
|
15
+6%
|
16
+9%
|
18
+10%
|
18
+1%
|
19
+3%
|
|
| EPS (Diluted) |
1.39
N/A
|
1.42
+2%
|
1.41
-1%
|
1.36
-4%
|
0.89
-35%
|
0.71
-20%
|
0.64
-10%
|
0.7
+9%
|
0.89
+27%
|
0.93
+4%
|
0.93
N/A
|
0.92
-1%
|
1
+9%
|
1.09
+9%
|
1.18
+8%
|
1.25
+6%
|
1.37
+10%
|
1.51
+10%
|
1.52
+1%
|
1.57
+3%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
